Edwards Lifesciences Reaffirms 2026 Guidance Following Medicare TAVR Decision

04:25 AM EDT, 09/11/2026 (MT Newswires) -- Edwards Lifesciences (EW) said Thursday it has maintained its 2026 financial outlook after US health regulators released an updated national coverage decision for transcatheter aortic valve replacement. The adoption of the revised coverage policy is expected to require time to take effect, the company said. The company plans to share its 2027 and long-term financial projections at an investor conference in December, it said.